GET DAILY SIGNALSQuanterix (QTRX) Analyst Targets Point to a Modest +12% Upside
Key Takeaways
- The central target of $3.25 is the average of the verified analyst price targets that sit above the current share price, since the overall mean of all valid targets (roughly $3.17) is less than 10% above the latest price.
- Shares of Quanterix Corporation (QTRX) last traded near $2.90, so reaching $3.25 implies an upside of roughly 12%.
- Coverage is thin and cautious: the current analyst price target range is approximately $3.00 to $3.50, with an overall consensus rating of Hold.
- The strongest support comes from an expanding revenue base and a recently raised target from TD Cowen, while persistent, sizable net losses are the principal headwind.
- The stock has been deeply de-rated, down about 42% over the past year and roughly 94% over five years, with a 52-week range of $2.15 to $8.77.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- Interested in automated insights? Explore Trending AI Robots to see AI-driven strategies in action.
Analyst Price Targets and Consensus View
Quanterix Corporation (QTRX), a Billerica, Massachusetts-based life sciences company known for its ultra-sensitive Simoa biomarker-detection platform, carries only a small analyst following today. Recent data shows roughly two to three covering firms with a consensus rating of Hold, and a current 12-month stock price target range of approximately $3.00 to $3.50.
The overall average analyst price target sits near $3.17, which is only about 9% above the latest price. Because that falls short of a meaningful move, the $3.25 central target used here reflects the average of the verified targets that are above the current price, giving a more representative picture of the upside the bulls on the name are modeling. For context, the full current range runs from about $3.00 on the cautious end to $3.50 on the high end.
The most recent revision came from TD Cowen, which raised its price target to $3.50 from $3.00 while keeping a Hold rating. Notably, targets were far higher a year earlier — several firms had carried $5 to $8 targets in late 2025 — but those figures have since been cut sharply as the share price collapsed. Analyst views differ mainly on how quickly Quanterix can narrow its losses and on whether its diagnostic pipeline can convert research demand into recurring, higher-margin revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $2.90 and a market capitalization of roughly $137 million, a move to $3.25 requires an advance of about 12% — a modest move in percentage terms relative to the stock's historical volatility, but a meaningful one given its multi-year downtrend. The shares trade at about 0.9 times trailing revenue and below book value, reflecting deep investor skepticism.
Trailing-twelve-month revenue of roughly $153 million has been growing, but the company continues to post large losses, with a trailing net loss near $123 million and EPS (earnings per share) of about -$2.63. The path toward the target therefore hinges less on a re-rating and more on evidence that growth is translating into improving profitability and cash flow.
What Could Support a Move Toward the Target
- Top-line momentum: revenue has expanded year over year, providing a foundation for leverage if cost discipline improves.
- Analyst revisions: TD Cowen's target increase to $3.50 signals that at least one covering firm sees improving value after the sharp de-rating.
- Balance-sheet cushion: cash of roughly $93 million against modest debt gives the company runway to invest while it works toward profitability.
- Diagnostics opportunity: Quanterix's ultra-sensitive Simoa technology targets high-value neurology biomarkers such as p-Tau 217 and NfL, a growing precision-medicine niche.
What Could Prevent the Target From Being Reached
- Persistent losses: a trailing net loss of about $123 million keeps profitability and free cash flow firmly negative.
- Thin, cautious coverage: with only a handful of analysts and a consensus Hold, there is limited institutional sponsorship to lift the multiple.
- Long-term de-rating: the stock is down about 94% over five years, indicating structural investor skepticism that could cap rallies.
- Execution risk: converting research instrument and consumable sales into durable, higher-margin diagnostic revenue remains unproven at scale.
Technical Levels and Market Structure
The 52-week range of $2.15 to $8.77 underscores how far the stock has fallen. Near-term, the $3.00 area is an important psychological and round-number level, while $3.50 represents both the top of the current analyst range and a nearby supply zone. The $2.15 low is the key downside support level to monitor, as a break below it would extend the long-term downtrend and make the $3.25 objective substantially harder to reach.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though the precise horizon can vary by firm. The most important near-term catalyst is the company's third-quarter 2026 earnings release, scheduled for November 9, 2026. Investors should watch revenue growth, gross margin, net loss trends, cash burn, and any updates to guidance or to the diagnostic pipeline, as well as any further analyst target changes or rating actions. From what I see, monitoring these metrics closely will be key in the coming weeks.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, track positions, and identify changing trends more efficiently than scanning charts manually. For investors following QTRX, tools like this can help flag shifts in momentum before they are obvious in the news cycle.
Final Assessment
The question of whether Quanterix (QTRX) can reach $3.25 is ultimately a question of whether a modest, roughly 12% rebound is achievable from a deeply depressed base. The $3.25 figure — the average of the analyst targets above the current price, against a full range of about $3.00 to $3.50 and an overall mean near $3.17 — is a conservative objective, not a prediction. Supporting the case are growing revenue, a recently raised target, and a solid cash position. Working against it are large ongoing losses, thin and cautious analyst coverage, and a multi-year de-rating. With earnings due November 9, 2026, the next print and any accompanying revisions will likely determine whether the modest recovery the remaining bulls are modeling can begin to take shape.
Using Tickeron AI Tools for Deeper Research
In my own process, I find Tickeron’s AI Daily Buy/Sell Signals particularly useful for tracking momentum shifts in names like this one. The platform scans thousands of stocks in real time and delivers clear signals based on technical and market data, which helps me cross-check analyst views without spending hours on manual chart reviews. It is one tool I keep handy when evaluating opportunities in thinly covered stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QTRX's Stochastic Oscillator is sitting in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for QTRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 22 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Moving Average Convergence Divergence Histogram (MACD) for QTRX turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
QTRX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on QTRX as a result. In 78 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
Following a +8.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 116 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.579) is normal, around the industry mean (4.209). P/E Ratio (-1.109) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. QTRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of protein diagnostic platform
Industry MedicalNursingServices
Advertisement